Pembrolizumab May Be an Alternative to Chemo for Select Patients With Gastric Cancers
Select patients with advanced gastric or gastroesophageal junction cancer may benefit from initial therapy with pembrolizumab, according to the KEYNOTE-062 trial.
Using Germline Testing to Inform Treatment Decisions in Breast Cancer
Ahead of the ASCO Annual Meeting, we discuss the use of germline testing and PARP inhibitors in patients with breast cancer with Jennifer K. Litton, MD.
Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy
Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.
Using Cannabis as a Palliative Treatment in Patients With Cancer
Ahead of the ASCO Annual Meeting, we discuss the use of cannabis as a palliative treatment in patients with cancer with Claude Cyr, MD.
Using Genomic Profiling to Guide Treatment Decisions for ER-Positive Breast Cancers
Ahead of the ASCO Annual Meeting, we discuss the use of genomic profiling to guide treatment decisions for ER+ breast cancer patients with Harold J. Burstein, MD, PhD.
ASCO 2019 Meet & Greet
Come visit us at our booth in the Exhibit Hall (Booth #18104) at the 2019 ASCO Annual Meeting.
ASCO: Can Changes in Diet Reduce Deaths From Breast Cancer?
Researchers looked at whether eating a low-fat diet helped improve survival in breast cancer, in a study presented ahead of the ASCO Annual Meeting.
ASCO: Promising Start to Pediatric MATCH Trial
Approximately 25% of patients with tumor samples submitted to the Pediatric MATCH program have been matched to an investigational therapy at an interim analysis reported ahead of the ASCO Annual Meeting.
ASCO: Assessing Low-Dose Chemo in Older, Frail Patients With Gastroesophageal Cancer
Researchers assessed outcomes with different chemo regimen doses in elderly or frail patients with gastroesophageal cancer, in this study presented ahead of the ASCO Annual Meeting.
Can Circulating Tumor DNA Inform Breast Cancer Treatment?
In this video, Dr. Minetta Liu outlines current research into profiling breast cancer cell-free DNA in the blood, potentially to identify clinically aggressive breast cancer subtypes.
Exploring Current Tests, Treatments in Breast Cancer Management
In this video, Dr. Nancy Davidson highlights current and next-generation diagnostics and therapies in breast cancer, as well as the need for “team science” in clinical trials.
Why Haven’t Older Adults Been Included in More Oncology Clinical Trials?
In this video, Dr. Arti Hurria discusses resources addressing the disconnect between cancer as a growing problem in the elderly and the fact that clinical trials mostly enroll younger patients.
Tools and Tweaks to Improve Sleep Quality in Patients With Cancer
In this video, Dr. Jun Mao describes practical changes that have boosted sleep quality in cancer patients, and highlights results of a study showing sleep benefits from both CBT and acupuncture.
Strategies for Communicating Treatment Risks and Uncertainty of Outcomes
In this video, Professor Dame Lesley Fallowfield explains why oncologists need to be aware of their own tolerance of uncertainty before discussing possible treatment risks and outcomes with patients.
FGFR Inhibitor Shows Promise in Advanced Urothelial Carcinoma
A phase II study found that the FGFR inhibitor erdafitinib yields a good response rate and was well tolerated in patients with urothelial carcinoma and FGFR alterations.
Higher OS With Neoadjuvant Chemo-RT in Pancreatic Cancer
In PREOPANC, the 2-year survival rate was significantly higher for patients who received neoadjuvant chemoradiotherapy vs standard care.
Bevacizumab Rechallenge Benefit in Recurrent Ovarian Cancer?
New data suggest adding bevacizumab to chemotherapy may prolong PFS in patients with recurrent ovarian cancer.
In DLBCL, Polatuzumab Combo Yields ‘Marked Improvement’ in CR, PFS, OS
Polatuzumab vedotin administered with bendamustine and rituximab significantly improved PET-based CR rates, PFS, and OS in DLBCL but not FL.
New Role for Maintenance Chemo in Rhabdomyosarcoma?
Six months of maintenance chemotherapy improved OS in children with high-risk rhabdomyosarcoma.
AR-V7 Key in Tx of mCRPC
In this video, Dr. Andrew Armstrong explains why AR-V7–positive men rarely benefit from abiraterone or enzalutamide, and advises on AR-V7 testing as a clinical tool.
Should mFOLFIRINOX Be Standard of Care in Adjuvant Tx of Pancreatic Cancer?
Compared with gemcitabine, mFOLFIRINOX improved outcomes for all endpoints when used in the adjuvant setting.
Can mRCC Patients Be Spared Debulking Nephrectomy?
In this video, Dr. Daniel George discusses CARMENA, which asked if cytoreductive surgery is necessary in the age of active systemic therapy for mRCC.
Analysis Highlights Changes in 8th Edition AJCC Melanoma Staging System
“Now that effective adjuvant therapy has arrived in melanoma, accurate staging and patient selection to optimize a risk/benefit ratio is crucial,” emphasizes lead author Max Madu.
Evolving Use of ICIs and Targeted Tx in NSCLC and SCLC
In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.
Pembrolizumab Is Effective in Unresectable Melanoma, at 4-Year Follow-Up
After 4 years of follow-up, pembrolizumab demonstrated durable antitumor activity and improved outcomes over ipilimumab in advanced melanoma.
Determining the Role of the Gut Microbiome in Melanoma Treated With Anti–PD-1 ICIs
Patients who responded to anti–PD-1 therapy and experienced prolonged progression-free survival had a much greater diversity of gut bacteria.
Noninferiority of Neoadjuvant Chemo Cannot Be Confirmed in Ovarian Cancer Trial
The noninferiority of neoadjuvant chemotherapy vs upfront surgery could not be confirmed with regard to overall survival in patients with ovarian, tubal, and peritoneal cancers.
Olaparib Plus Vistusertib Promising in Early Trial of Endometrial, Other Cancers
The combination of the PARP inhibitor olaparib with the mTORC1/2 inhibitor vistusertib had promising activity across endometrial, ovarian, and triple-negative breast cancers.
Exploring the Changing Landscape of ICI Tx in NSCLC
In this video, Dr. Leena Gandhi discusses KEYNOTE-042, a study of pembrolizumab vs chemotherapy in NSCLC (abstract LBA4), and other key ICI trials reported at ASCO 2018.
Newer Targeted Approaches in Medullary Thyroid Cancer
In this video, Dr. Manisha Shah highlights new and emerging targeted therapies for medullary thyroid cancer, including research presented at ASCO 2018.
